Shared on 29 Oct 25
Fair value Increased 1.52%Hikma Pharmaceuticals' analyst price target was slightly raised to £25.40 from £25.02, as analysts cite updated growth and profitability forecasts. This comes despite recent downward adjustments in individual firm targets.
Shared on 04 Sep 25
Fair value Decreased 0.59%US, Europe, And MENA Expansion Will Boost Global Pharmaceutical Demand
Hikma Pharmaceuticals’ Future P/E ratio has dropped sharply, indicating improved valuation relative to earnings expectations, while revenue growth forecasts remain steady, resulting in the consensus price target edging down slightly from £25.17 to £25.02. What's in the News Hikma maintained full-year 2025 group revenue growth guidance of 4–6%, with core operating profit expected at $730–770 million; injectable segment revenue growth is guided at 7–9%, branded revenue at 6–7%, and Rx revenue broadly flat versus 2024.
Shared on 01 May 25
Fair value Increased 4.20%US, Europe, And MENA Expansion Will Boost Global Pharmaceutical Demand
Shared on 24 Apr 25
R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Increased 2.50%R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 4.03%R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 1.32%R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Decreased 2.06%R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 4.66%R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
AnalystConsensusTarget has decreased revenue growth from 5.6% to 4.8% and decreased future PE multiple from 15.8x to 13.9x.